Drug–Drug Conjugates as Intelligent Preclinical Platforms for Targeted Cancer Therapy
- 1Pharmacological and Diagnostic Research Center, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman 19328, Jordan
Abstract
Drug–drug conjugates (DDCs), in which two active pharmaceutical ingredients (APIs) are linked covalently within a single molecular structure to produce a synergistic therapeutic effect, represent an emerging category of single-molecule therapeutics. These conjugates differ from conventional combination therapies by utilising well-defined covalent chemical linkages (such as amide, ester, disulfide, and carbamate bonds), usually coupled with self-immolative spacers. This structural architecture ensures synchronised intracellular delivery and controlled, stimulus-responsive release of the parent APIs in a fixed stoichiometry. In oncology, this strategy is especially attractive because it reduces systemic toxicity, improves intratumoral accumulation, and helps bypass resistance mechanisms that limit conventional chemotherapy. Recent advances in linker chemistry, tumour-responsive cleavage, and self-immolative systems have shifted these constructs from simple mutual prodrugs toward intelligent, adaptive delivery platforms. This review summarizes how DDCs mitigate off-target effects, overcome cellular resistance, exploit tumor-specific triggers, and evolve into next-generation translational cancer therapeutics.
Related
- MXene quantum dot polymer nanocomposites as smart platforms for targeted drug delivery and multifunctional biomedical applications: an updated review
- Computational and Experimental Studies of PSMA-Targeted Conjugates Designed for Subcellular Delivery of Theranostic Radiometals to Prostate Cancer Cells
- Radiolabeling and Preclinical Evaluation of [77Br]hGTS13, an xCT-Targeted Small Molecule
- Radiopharmaceuticals and theranostics: reshaping cancer diagnosis and therapy with targeted radionuclides
- Targeted delivery of celastrol and siRNA via macrophage biomimetic nanoparticles for doxorubicin-induced cardiomyopathy therapy
BibTeX
@article{abufara2026drugdrug,
title = {{Drug–Drug Conjugates as Intelligent Preclinical Platforms for Targeted Cancer Therapy}},
author = {Aya Abufara and Mohamad A. K. Mousa and Hamdi Nsairat},
journal = {Biomolecules},
year = {2026},
month = sep,
doi = {10.3390/biom16101417},
url = {https://www.mdpi.com/2218-273X/16/10/1417},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Drug–Drug Conjugates as Intelligent Preclinical Platforms for Targeted Cancer Therapy
AU - Aya Abufara
AU - Mohamad A. K. Mousa
AU - Hamdi Nsairat
PY - 2026
DA - 2026/09/30
JO - Biomolecules
DO - 10.3390/biom16101417
UR - https://www.mdpi.com/2218-273X/16/10/1417
AB - Drug–drug conjugates (DDCs), in which two active pharmaceutical ingredients (APIs) are linked covalently within a single molecular structure to produce a synergistic therapeutic effect, represent an emerging category of single-molecule therapeutics. These conjugates differ from conventional combination therapies by utilising well-defined covalent chemical linkages (such as amide, ester, disulfide, and carbamate bonds), usually coupled with self-immolative spacers. This structural architecture ensures synchronised intracellular delivery and controlled, stimulus-responsive release of the parent APIs in a fixed stoichiometry. In oncology, this strategy is especially attractive because it reduces systemic toxicity, improves intratumoral accumulation, and helps bypass resistance mechanisms that limit conventional chemotherapy. Recent advances in linker chemistry, tumour-responsive cleavage, and self-immolative systems have shifted these constructs from simple mutual prodrugs toward intelligent, adaptive delivery platforms. This review summarizes how DDCs mitigate off-target effects, overcome cellular resistance, exploit tumor-specific triggers, and evolve into next-generation translational cancer therapeutics.
SN - 2218-273X
ER -